Tag Archives: Vernon Bernardino

Analysts Offer Insights on Healthcare Companies: Geron (NASDAQ: GERN), Revance Therapeutics (NASDAQ: RVNC) and Electrocore (NASDAQ: ECOR)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Geron (GERN – Research Report), Revance Therapeutics (RVNC – Research Report) and Electrocore (ECOR – Research Report) with bullish sentiments. Geron (GERN)

H.C. Wainwright Initiates a Buy Rating on AIkido Pharma (AIKI)

AIkido Pharma (AIKI – Research Report) received a Buy rating and a $2.00 price target from H.C. Wainwright analyst Vernon Bernardino today. The company’s shares closed last Friday at $0.87. According to TipRanks.com, Bernardino is a 5-star analyst with an

H.C. Wainwright Reiterates a Buy Rating on Seres Therapeutics (MCRB)

In a report released today, Vernon Bernardino from H.C. Wainwright reiterated a Buy rating on Seres Therapeutics (MCRB – Research Report), with a price target of $25.00. The company’s shares closed last Tuesday at $6.96, close to its 52-week low

Analysts Are Bullish on These Healthcare Stocks: Aridis Pharmaceuticals (ARDS), Verastem (VSTM)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aridis Pharmaceuticals (ARDS – Research Report) and Verastem (VSTM – Research Report) with bullish sentiments. Aridis Pharmaceuticals (ARDS) In a report released

Analysts Offer Insights on Healthcare Companies: Geron (NASDAQ: GERN), Cara Therapeutics (NASDAQ: CARA) and Applied DNA Sciences (NASDAQ: APDN)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Geron (GERN – Research Report), Cara Therapeutics (CARA – Research Report) and Applied DNA Sciences (APDN – Research Report) with bullish sentiments.

Achieve Life Sciences (ACHV) Received its Third Buy in a Row

After Maxim Group and Ladenburg Thalmann & Co. gave Achieve Life Sciences (NASDAQ: ACHV) a Buy rating last month, the company received another Buy, this time from H.C. Wainwright. Analyst Vernon Bernardino reiterated a Buy rating on Achieve Life Sciences